This clinical trial is intended to evaluate the impact, efficacy, and safety of Chitosan formulated adhesion inhibitor, SurgiShield when used in the process of wound healing after endoscopic sinus surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
33
in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site merocel in the inflated state maintained for 36\~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site
Chungbook National University Hospital
Chungju, ChoongChungBukDo, South Korea
Dankook University Hospital
Cheonan, Chungcheongnam-do, South Korea
Adhesion Rate
Adhesion rate at 2 weeks after ESS(endoscopic sinus surgery)
Time frame: at 2 weeks
Adhesion Rate
Adhesion rate at 1 and 4 weeks after ESS(endoscopic sinus surgery) Bleeding score at 0,2,4,6,8,10 minutes after ESS
Time frame: at 1 and 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.